Teva Pharmaceutical Industries Limited (TEVA) Q2 2010 Earnings Conference Call July 27, 2010 8:30 AM ET Executives Elana Holzman – IR Shlomo Yanai – President and CEO Eyal Desheh – CFO Gerard Van Odijk – President and CEO, Teva Europe Bill Marth – President and CEO, Teva North America Ben-Zion Weiner – Chief R&D Officer Moshe Manor – Group VP, Global Branded Products Analysts Randall Stanicky – Goldman Sachs Richard Silver – Barclays Capital Chris Schott – JP Morgan Chase & Company Ronny Gal – Sanford C. Bernstein and Co. David Amsilumer – Hyper Jafford Gregg Gilbert – Bank of America David Buck – Buckingham Research Group John Boris – Citigroup Mark Goodman – UBS Corey Davis with Jefferies & Co. David Maris – Credit Agricole PresentationOperator
Greetings and welcome to the Teva Pharmaceutical Industries Ltd. Second Quarter 2010 Results Conference Call. (Operator instructions) It is now my pleasure to introduce your host, Ms. Elana Holzman, Senior Director of Investor Relations. Thank you, Ms. Holzman, you may begin. Elana Holzman Thank you, Diego. Good morning and good afternoon everyone. Welcome to Teva's second quarter 2010 earnings conference call. We hope you had a chance to review our press release, which we issued earlier this morning. A copy of the press release is available on our website at www.tevapharm.com. Additionally, we are conducting a live web cast of this call that is also available on our website. Today, we are joined by Shlomo Yanai, President and CEO; Eyal Desheh, Chief Financial Officer; Bill Marth, President and CEO of Teva North America Pharmaceutical; Moshe Manor, Group Vice President, Global Branded Products; and Dr. Gerard Van Odijk, President and CEO of Teva Europe and Dr. Ben-Zion Weiner, Teva's Chief R&D Officer.